Q-omics provides the consensus-scored PGAM1P6 profile across patient tissues and cancer cell-line models. PGAM1P6 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, PGAM1P6 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, PGAM1P6 RNA expression shows 8,996 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight CESC, HNSC, and LAML as cancer lineages where PGAM1P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PGAM1P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PGAM1P6 survival associations across molecular data types. PGAM1P6 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PGAM1P6 RNA expression–survival associations across cancer types. High PGAM1P6 expression shows unfavorable associations in UCEC, CHOL and ESCA, but favorable associations in CESC, HNSC and SKCM. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify CESC as the clearest survival context for PGAM1P6 RNA expression.
This table summarizes PGAM1P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for PGAM1P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PGAM1P6 shows higher tumor expression in HNSC, KICH, LIHC, COAD, LUSC and CHOL. The HNSC box plot shows higher PGAM1P6 RNA expression in tumor versus normal tissue (log2 FC = +0.091, t-test p = .001).
This table shows molecular features associated with PGAM1P6 in patient tissues and cancer cell lines. In patient samples, PGAM1P6 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
